Chinese Chemical Letters, Journal Year: 2024, Volume and Issue: unknown, P. 110771 - 110771
Published: Dec. 1, 2024
Language: Английский
Journal of Pharmacological and Toxicological Methods, Journal Year: 2025, Volume and Issue: 131, P. 107583 - 107583
Published: Jan. 23, 2025
Language: Английский
Citations
2
BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)
Published: Aug. 28, 2024
Recent studies have increasingly linked Ephrin receptor B2 (EPHB2) to cancer progression. However, comprehensive investigations into the immunological roles and prognostic significance of EPHB2 across various cancers remain lacking.
Language: Английский
Citations
13
Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975
Published: Aug. 27, 2024
Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.
Language: Английский
Citations
9
Clinical Reviews in Allergy & Immunology, Journal Year: 2025, Volume and Issue: 68(1)
Published: Feb. 11, 2025
Language: Английский
Citations
0
Chemical Biology & Drug Design, Journal Year: 2025, Volume and Issue: 105(2)
Published: Feb. 1, 2025
ABSTRACT Various substituted benzothiazole‐thiadiazole‐based ketones 4a‐i and 6a‐c were synthesized characterized by the IR, NMR, MS spectral data. The DFT study of 4 6 displayed matched configurations their HOMO LUMO, with exception nitrophenyl derivatives, whose extended over entire molecule. Meanwhile, antiproliferative effectiveness produced was evaluated against diverse cell lines compared reference drug Erlotinib. exhibited variable inhibitory effects, for example, ketone 6a has most potent activity versus Panc‐1 (IC 50 = 9.34 ± 0.18 μM), whereas 4i showed proper HepG2 10.91 0.23 4a strong MCF‐7 cells 5.66 0.16 μM). Moreover, H5N1 antiviral efficacy assessed via a plaque reduction assay, using amantadine as drug. Ketones 2a , 4e 4g 100% inhibition, while lowest toxic concentration (TC 61 μg/μL). Furthermore, molecular docking results revealed that had highest binding score owing to several interactions amino acids 1JU6 residues. Finally, SwissADME analysis provides key insights into pharmacokinetic properties.
Language: Английский
Citations
0
Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 47
Published: March 13, 2025
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide, characterized by its complex pathogenesis and poor therapeutic outcomes. Despite recent advances in targeted molecular therapies, immune checkpoint inhibitors (ICIs), radiotherapy, conventional chemotherapy, five-year survival rate for this neoplasm remains dismally low. The progress nanotechnology has revolutionized cancer treatment years. These provide unprecedented opportunities to overcome current limitations different modalities. This review provides a comprehensive analysis how interfaces with tumor microenvironment (TIME) HCC can present new frontier interventions HCC. We critically overview latest developments nanoparticle-based delivery systems various drugs also other antitumor agents like thermal therapy radiotherapy. highlight unique ability nanoparticles modulate immunosuppressive (TME) enhance efficacy. Furthermore, we analyze emerging strategies that exploit nanoformulations biological barriers drug bioavailability treatment.
Language: Английский
Citations
0
Aspects of Molecular Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 100073 - 100073
Published: March 1, 2025
Language: Английский
Citations
0
The EPMA Journal, Journal Year: 2025, Volume and Issue: unknown
Published: March 22, 2025
Language: Английский
Citations
0
Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 930 - 930
Published: April 9, 2025
The advent of immune checkpoint blockade (ICB) has transformed cancer immunotherapy, enabling remarkable long-term outcomes and improved survival, particularly with ICB combination treatments. However, clinical benefits remain confined to a subset patients, life-threatening immune-related adverse effects pose significant challenge. This limited efficacy is attributed heterogeneity, which mediated by ligand–receptor interactions, exosomes, secreted factors, key transcription factors. Oncogenic regulators like E2F1 MYC drive metastatic tumor environments intertwine immunoregulatory pathways, impairing T cell function reducing immunotherapy effectiveness. To address these challenges, FDA-approved biomarkers, such as mutational burden (TMB) programmed death-ligand 1 (PD-L1) expression, help identify patients most likely benefit from ICB. Yet, current biomarkers have limitations, making treatment decisions difficult. Recently, cells—the primary target ICB—have emerged promising biomarkers. review explores the relationship between drivers response, emphasizes role CD8+ cells in predicting monitoring efficacy. Tumor-infiltrating correlate positive many cancers, yet obtaining tissue remains complex, limiting its practical use. Conversely, circulating subsets are more accessible shown promise predictive Specifically, memory progenitor exhausted associated favorable responses, while terminally negatively Ultimately, combining enhances accuracy, demonstrated integrating TMB/PD-L1 expression frequency. Computational models incorporating signatures could further refine patient stratification, advancing personalized immunotherapy.
Language: Английский
Citations
0
Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: 6
Published: April 27, 2025
Neoantigen-based immunotherapy has emerged as a transformative approach in cancer treatment, offering precision medicine strategies that target tumor-specific antigens derived from genetic, transcriptomic, and proteomic alterations unique to cells. These neoantigens serve highly specific targets for personalized therapies, promising more effective tailored treatments. The aim of this article is explore the advances neoantigen-based highlighting successful treatments such vaccines, tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor-engineered T cells therapy (TCR-T), chimeric antigen receptor (CAR-T), particularly types like glioblastoma (GBM). Advances technologies next-generation sequencing, RNA-based platforms, CRISPR gene editing have accelerated identification validation neoantigens, moving them closer clinical application. Despite results, challenges tumor heterogeneity, immune evasion, resistance mechanisms persist. integration AI-driven tools multi-omic data refined neoantigen discovery, while combination therapies are being developed address issues suppression scalability. Additionally, discusses ongoing development immunotherapies targeting mutations, emphasizing need continued collaboration between computational experimental approaches. Ultimately, cutting-edge research holds potential revolutionize care, hope targeted
Language: Английский
Citations
0